BGLC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for BioNexus Gene Lab Corp (BGLC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess BioNexus Gene Lab Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BGLC News & Events

Events Timeline

No data

News

7.5

2025-12-02Globenewswire

BioNexus Gene Lab Corp. Secures $500 Million Equity Purchase Agreement with ARC Group

7.5

2025-10-20Newsfilter

BioNexus Gene Lab Corp Enters Strategic Partnership Agreement with BirchBioMed Inc.

4.5

2025-07-30TipRanks

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

People Also Watch

Frequently Asked Questions

What is BioNexus Gene Lab Corp (BGLC) stock price today?

The current price of BGLC is 3.99 USD — it has decreased -0.5 % in the last trading day.

What is BioNexus Gene Lab Corp (BGLC)'s business?

BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.

What is the price predicton of BGLC Stock?

Wall Street analysts forecast BGLC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BGLC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is BioNexus Gene Lab Corp (BGLC)'s revenue for the last quarter?

BioNexus Gene Lab Corp revenue for the last quarter amounts to 2.54M USD, decreased -3.29 % YoY.

What is BioNexus Gene Lab Corp (BGLC)'s earnings per share (EPS) for the last quarter?

BioNexus Gene Lab Corp. EPS for the last quarter amounts to -0.39 USD, decreased -48.00 % YoY.

What changes have occurred in the market's expectations for BioNexus Gene Lab Corp (BGLC)'s fundamentals?

The market is revising No Change the revenue expectations for BGLC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -27.85%.

How many employees does BioNexus Gene Lab Corp (BGLC). have?

BioNexus Gene Lab Corp (BGLC) has 30 emplpoyees as of January 08 2026.

What is BioNexus Gene Lab Corp (BGLC) market cap?

Today BGLC has the market capitalization of 9.12M USD.